



DexTech
Know-how in Translational Research

DexTech Medical AB
Year-end report July 1, 2021 - June 30, 2022

By "Company" or "DexTech" is meant DexTech Medical AB with organization number 556664-6203.

Summary of the fourth quarter (2022-04-01 – 2022-06-30)

- Net sales amounted to MSEK 0,0 (0,0)
- Operating profit/loss amounted to MSEK -2,1 (-1,5)
- Earnings per share* SEK -0.11 (-0.10)

** Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 14,920,478. Amounts in brackets refer to the corresponding period last year.*

Summary of the financial year (2021-07-01 – 2022-06-30)

- Net sales amounted to MSEK 0,0 (0,0)
- Operating profit/loss amounted to MSEK -5,3 (-6,1)
- Earnings per share* SEK -0.31 (-0.41)
- Cash and cash equivalents at the end of the period amounted to MSEK 35,5 (3,5)

** Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 16,790,364. For the comparison period, the average number of shares was 14,920,478. Amounts in brackets refer to the corresponding period last year.*

CEO's comment

The clinical myeloma study with the Company's drug candidate OsteoDex, which was financed via a rights issue in December 2021 that brought the company SEK 37 million after issue costs, continues according to plan. The study application to the Swedish Medicines Agency has now been approved and permission was announced on August 10, 2022. The study will include 20 patients and will be conducted at 5 hospital centers in Sweden and Norway. The study is estimated to start during quarter 1 2023 at the latest and is estimated to be completed during quarter 3 2024.

Our previous preclinical studies regarding OsteoDex's effect on various myeloma cell cultures clearly show a strong tumor cell-killing effect. With our clinical experience of OsteoDex's effect on disease processes in the skeleton (mCRPC), we have reason to be optimistic about the myeloma study.

At the extraordinary general meeting on 11 May, Andreas Segerros was elected to the board and was appointed chairman of the board on the same day. Andreas Segerros has long and solid experience with executive positions within the international pharmaceutical industry in Europe, the USA and Japan. Andreas Segerros will be a key person in the Company's continued development, this in perspective of his previous experience and associated network.

Anders R Holmberg
CEO

DexTech Medical

Significant events during the financial period (July 2021 – June 2022)

Ahead of the upcoming study, the company strengthens the board by co-opting Håkan Åström, who has extensive experience from leading positions in the international pharmaceutical industry. Håkan Åström will assist the Company in developing business opportunities based on the candidate portfolio.

DexTech announced on August 24 that OsteoDex (ODX) pre-clinical results regarding the effect on multiple myeloma (MM) are so convincing that the company began planning a clinical "proof of concept study" (short study with a limited number of patients). MM is a form of blood cancer based on plasma cells in the bone marrow that, among other things, causes the breakdown of the skeleton, similar to skeletal metastases in prostate cancer (CRPC). MM is an incurable cancer disease where a number of different drugs are used to slow down the process. Patients eventually become resistant to existing drugs that often have severe side effects.

ODX's unique mechanism of action, together with very mild side effects, makes the drug a strong candidate for treatment of MM as well. The global market size for MM in 2018 was \$ 19.5 billion and is expected to grow to \$ 31 billion by 2026 (<https://www.fortunebusinessinsights.com/multiple-myeloma-market-102693>). The figures indicate a more than twice as large market size compared to CRPC. The company believes that, given MM's market size and ODX's clear potential for the disease, it is of the highest priority to obtain supplementary clinical data.

On October 7, 2021, DexTech Medical AB ("DexTech") announced that preparations for the "proof of concept" study with the company's main candidate OsteoDex (ODX) in multiple myeloma (MM) are proceeding according to plan.

The company's continued main track is ODX for the treatment of mCRPC, but the supplemented positive ODX-MM results strengthen, according to the board's assessment, the possibilities for a favorable license agreement – thus an agreement that reflects ODX's actual value.

The proof of concept study is planned to begin in fiscal year 2022 and include approx. 20 patients. Partial results from the study will be announced gradually during the course of the study (non-blinded study). It is expected to continue approx. 24 months from the start of studies. The company will inform the market about the start of studies and a more detailed arrangement when the study plan has been determined.

During December 2021, DexTech carried out a rights issue that provided the Company with SEK 46.3 million before issue costs of SEK 9.2 million.

DexTech announced on January 24 that the Rights Issue has been registered with the Swedish Companies Registration Office and that the last day for trading with BTA was January 27, 2022 and the closing date is January 31, 2022. Shares are expected to be distributed to VP account / depository on February 2, 2022.

On April 6, DexTech announced the Board's decision to strengthen the Company's organization with the main focus on future business based on DexTech's unique platform technology and research portfolio. Andreas Segerros is proposed as the new Chairman of the Board and will lead the work of further strengthening the Board with industry expertise and implementing a strengthening of the management. Andreas Segerros has long and solid experience with executive positions in the international pharmaceutical industry, in Europe, the USA and Japan.

On 11 May, an extraordinary general meeting was held where a decision was made to expand the board by one person and to elect Andreas Segerros to the board. At the subsequent constitutive board meeting, Andreas Segerros was elected chairman of the board.

Events after the end of the financial year

DexTech announced on August 10, 2022 that the application for a phase 1 study regarding OsteoDex's effect on patients with multiple myeloma has been approved and granted permission by the Swedish Medicines Agency. The study will include 20 patients and will be conducted at 5 hospital centers in Sweden and Norway. The study is estimated to start during quarter 1 2023 at the latest and is estimated to be completed during quarter 3 2024.

Financial overview

| | Fourth Quarter | | 12 Months | |
|---|----------------|------------|------------|------------|
| | 2022-04-01 | 2021-04-01 | 2021-07-01 | 2020-07-01 |
| | 2022-06-30 | 2021-06-30 | 2022-06-30 | 2021-06-30 |
| Net sales, KSEK | – | – | – | – |
| Operating profit/loss, KSEK | -2 055 | -1 488 | -5 269 | -6 075 |
| Profit/loss before tax, SEK* | -0,11 | -0,10 | -0,31 | -0,41 |
| Cash flow from operating activities, KSEK | | | -2 000 | -2 000 |
| Cash flow from investing activities, KSEK | | | -3 115 | -634 |
| Cash flow from financing activities, KSEK | | | 37 131 | – |
| Cash flow for the year | | | 32 016 | -2 634 |
| <i>* before dilution</i> | | | | |
| | 2022-06-30 | 2021-06-30 | | |
| Cash and cash equivalents, KSEK | 35 473 | 3 457 | | |
| Total assets, KSEK | 39 589 | 7 234 | | |
| Equity ratio, % | 98 | 97 | | |

Results, The fourth quarter, April – June 2022

Turnover and earnings

The company had no sales during the fourth quarter. Operating profit amounted to MSEK -2,1 (-1,5). During the third quarter, costs of MSEK 2,9 (0,2) were capitalized for drug development and patents. Operating expenses amounted to MSEK 4,9 (1,7) and consist of personnel costs MSEK 0,2 (0,2), other external expenses MSEK 3,5 (0,4) and depreciation MSEK 1,2 (1,1). Other external costs include costs for patents MSEK 0,1 (0,2) and regulatory control MSEK 2,8 (-) regarding the phase IIb study. Profit after tax amounted to MSEK -2,1 (-1,5).

Results, The financial year, July 2021 – June 2022

Turnover and earnings

The company had no sales during the fiscal year. Operating profit amounted to MSEK -5,3 (-6,1). During the first quarter, costs of MSEK 3,1 (0,6) were capitalized for drug development and patents. Operating expenses amounted to MSEK 8,4 (6,7) and consist of personnel costs MSEK 0,7 (0,7), other external expenses MSEK 4,6 (1,9) and depreciation MSEK 3,0 (4,1). Other external costs include costs for patents MSEK 0,3 (0,5) and regulatory control MSEK 2,8 (-) regarding the phase IIb study. Profit after tax amounted to MSEK -5,3 (-6,1).

Liquidity and financing

Cash and cash equivalents at the end of the period amounted to MSEK 35,5 (3,5).

Cash flow for the period amounted to MSEK 32,0 (-2,6), whereof 37,1 MSEK from the right issue.

Financing is done with equity. Equity at the end of the financial year amounted to MSEK 38,9 (7,0), corresponding to SEK 2.10 (0.47) per share. The equity / assets ratio was 98 (97) percent.

Working capital

During December 2021, DexTech carried out a rights issue that provided the Company with SEK 46.3 million before issue costs. DexTech received SEK 37.1 million net after issue costs of SEK 9.2 million. The rights issue in 2021 ensured continued operations until the end of 2024. The goal is for license revenues to finance operations thereafter.

DexTech Medical

Operations

DexTech Medical, org.no 556664-6203 based in Stockholm, develops drug candidates with application in urological oncology, primarily prostate cancer. The business began on August 9, 2004 and the Company was listed on the Spotlight Stock Market on June 19, 2014.

The company has a strong clinical foundation with valuable specialist expertise, from research laboratory and manufacturing to clinical oncology. Research and development are conducted cost-effectively through collaborations in a global network.

Based on a proprietary patented technology platform, GuaDex, the Company has developed four different drug candidates, OsteoDex, SomaDex, CatDex & GuaDex and a PSMA-binding conjugate, with patents / patent applications in several key markets.

- The company's main candidate, *OsteoDex*, for the treatment of skeletal metastases in castration-resistant prostate cancer, CRPC, has shown strong tumor-killing effect and potent inhibition of bone destruction after extensive preclinical studies. Following a successful phase I / IIa study in which the result shows high tolerability with only mild side effects and a clear effect in the highest dose group, a clinical phase IIb study (efficacy study) was initiated in autumn 2014. The complete clinical study report (CSR) from the phase IIb study for OsteoDex was completed in December 2018. The study conducted in Sweden, Finland, Estonia and Latvia included 55 well-defined patients with castration-resistant prostate cancer with skeletal metastases (mCRPC).
- *SomaDex* for the treatment of acromegaly, neuroendocrine tumors and palliative treatment for advanced prostate cancer. SomaDex is a drug candidate based on a body hormone, somatostatin for the treatment of acromegaly, neuroendocrine tumors and palliative therapy for advanced prostate cancer. SomaDex has undergone a Phase I clinical trial (in Sweden / Finland) and a Phase II pilot study in Mexico. The studies showed that SomaDex has few and mild side effects (phase I) and has a soothing effect (palliative) in advanced prostate cancer (pilot study).
- *CatDex & GuaDex*: GuaDex is the so-called. technology platform and is a charge-modified dextran molecule with tumor toxic properties (kills tumor cells) and is a development of CatDex.
- *PSMA-binding conjugate*, for target-specific treatment of mCRPC overexpressing PSMA (prostate-specific membrane antigen). The association is based on the platform, GuaDex.

DexTech's goal is to license the respective drug candidate by the latest phase II study. The technology platform, which can be likened to a "subway box" with multiple opportunities to build new molecules, can also be licensed.

The following parameters have been important for DexTech's positive development to date:

- modified generics with well-documented mechanisms of action that are patented, resulting in a lower risk of clinical development;
- early proof-of-concept data;
- strong clinical foundation with daily contact in clinical oncology;
- worked in networks, academically and commercially;
- minimized fixed costs
- capital has been dedicated to drug development and patents.

Prostate cancer

- Prostate cancer is the most common form of cancer in men in the western world.
- About 25% of those with prostate cancer develop incurable castration-resistant prostate cancer (CRPC) with skeletal metastases.
- Today there are only a handful of approved drugs that can extend the life of these patients. All of these medicines have more or less serious side effects. Each of these drugs currently has, or is expected to achieve, sales of over \$ 1 billion annually, so-called block-busters.

DexTech Medical

- After a limited time, the CRPC becomes resistant to the respective drugs, which means that the need for new supplemental life-extending medicines is great.
- DexTech's main candidate, OsteoDex, has the potential to become such a complementary drug.

The Phase IIb study

The original study protocol with ID ODX-002 was approved by the Swedish and Danish Medicines Agency in October 2014 (a placebo-controlled randomized multicenter phase II trial) for OsteoDex for the treatment of castration-resistant prostate cancer with skeletal metastases (CRPC). On October 27, 2015, DexTech decided to change the study design and provide all study patients with active substance (OsteoDex). This is a result of discussions with the Swedish Medical Products Agency in Uppsala and advice from "BigPharma". The study design was changed to active treatment for all patients. DexTech thus gains faster knowledge of the tumor-inhibiting effect in relation to dose, the effect parameter demanded by prospective licensees. DexTech also obeyed patients' requests for access to active substance and thus did not have to risk randomization to the placebo group. A decision on approval of the new study protocol with ID ODX-003 was made by the Swedish Medical Products Agency in Uppsala on 28/2 2016.

The primary purpose of the Phase II study was to document the efficacy of OsteoDex in the treatment of CRPC. The study included 55 well-defined CRPC patients. Patients were divided between three treatment arms (blinded distribution, 3 escalating dose levels of OsteoDex). The treatment was given for 5 months where OsteoDex was administered every two weeks. The study was conducted in Sweden (Norrlands University Hospital in Umeå, Southern Hospital in Stockholm and University Hospital in Örebro), in Finland (Tampere University Hospital), in Estonia (East Tallin Central Hospital and Tartu University Hospital) and in Latvia (Riga East University Hospital and Daugavpils Regional Hospital). The first patient received his first treatment in September 2016 at Southern Hospital in Stockholm.

In connection with these changes, the company chose to change the study organization by recruiting Crown-CRO Oy as GCP responsible (good clinical practice) for the OsteoDex study. Crown-CRO Oy specializes in oncology studies in the Nordic and Baltic countries. Crown-CRO Oy replaces the company's former partner SynteractHCR.

In June 2018, the last patients in DexTech's Phase IIb study for OsteoDex were completed. The work was then focused on the completion of the formal study report.

In early October 2018, DexTech was able to present the first results of the completed Phase IIb study for Osteodex. The results met the primary objective of the protocol.

Parts of the results, previously announced, were presented at the BioEurope Conference in Copenhagen in November 2018 and received with great interest.

In December 2018, the full CRO report from the Phase IIb study for Osteodex was completed. Fifty percent of patients completed the treatment (5 months, dose every two weeks). Of these, 52% showed stable disease (improved / unchanged) in skeletal metastasis. 35% of patients completing the treatment received reduced tumor burden in the skeleton. Most of the patients who received a reduced tumor burden in the skeleton had been treated with, and no longer responded to, two or more of the currently available drugs (docetaxel, cabazitaxel, abiraterone, enzalutamide, radium-223 dichloride) before recruitment to the study. This finding is of great importance for the continued clinical development of OsteoDex as the current patient group represents a significant so-called. "unmet medical need". The results show that OsteoDex has a significant inhibitory effect on the vicious cycle in the skeleton, i.e. the biological process that drives this disease and thus also to shortened survival. More than 50% of patients showed markedly lowered levels of bone metabolism markers and a particularly marked decrease was noted in 67% of patients for marker CTX, which reflects bone degradation. The effect on this marker as well as other markers related to skeletal metastasis reflects the biological effect of the OsteoDex molecule. Tolerability was remarkably good with only a few side effects. No patients had to discontinue treatment due to side effects and no OsteoDex-related serious adverse events (SAEs) were noted. The three dose arms in the protocol exhibited equivalent treatment effect. The interpretation is that even the lower doses are sufficient to saturate the metastatic areas of the skeleton. The results met the primary objective of the protocol.

On October 14, 2019, DexTech reported promising follow-up results from the company's Phase IIb

DexTech Medical

study on OsteoDex for the treatment of castration-resistant metastatic prostate cancer (mCRPC). Patients were followed for 24 months after end of OsteoDex treatment. The results as of October 14 2020 showed the following: 58 per cent of the patients with stable (unchanged) disease in skeletal metastasis at the end of treatment were alive; 48 per cent of the patients who discontinued the treatment or ended the treatment with progressive disease (progressive disease progression) were alive; 86 per cent of the patients who had objective response (reduction of existing skeletal metastases) were alive. The results indicate prolonged survival after OsteoDex treatment.

DexTech announced on June 12, 2020 that the randomized phase IIb study for the treatment of skeletal metastatic castration-resistant prostate cancer (mCRPC) had been completed, with 2-year follow-up results obtained from the last patients.

The primary endpoints of the study regarding markers for bone metabolism had been achieved. The majority of patients showed reduction in their skeletal markers in blood by the given treatment with OsteoDex. The treatment was very well tolerated (few and mild side effects) and good disease-inhibitory effect was seen even in the lowest doses. Objective responses were seen also in patients where the disease has progressed on treatments with several of currently available drugs for castration-resistant prostate cancer.

The study's secondary endpoints include overall survival 24 months after completion of treatment. Of the patients who responded to the treatment the median survival had not yet been achieved (> 27 months), compared with 14 months for the non-responders (significance, $p < 0.05$). The survival 2 years after the start of treatment was 65% for the patients who responded to the treatment, compared with 28% for the non-responders (significance, $p < 0.05$).

The results from the study were very positive and show that OsteoDex effectively slows down the tumor disease. Data regarding overall survival should be seen as an indication, as these data, for natural reasons, need to be confirmed in a much larger, so-called Phase III study.

None of the modern drugs is curative in castration-resistant prostate cancer and there is therefore a big unmet need for novel potent and well-tolerated drugs. OsteoDex has a clear potential to meet this need.

The continued clinical development of OsteoDex will be carried out by or together with a prospective licensee.

Extended preclinical program

OsteoDex has a mechanism of action against cancer cells that is general and therefore other cancers have also been investigated as possible indications in addition to mCRPC i.e., breast cancer, lung cancer and multiple myeloma.

Breast cancer

In November 2014, DexTech expanded the preclinical program with OsteoDex to include breast cancer. There are significant similarities between castration-resistant prostate cancer and advanced breast cancer regarding the tendency to metastasize to the skeleton. DexTech's preclinical studies to date have clearly shown that OsteoDex has promising potential for the treatment of this cancer as well. Through the Company's international network, extended preclinical studies are now being conducted regarding OsteoDex treatment for breast cancer. DexTech will own all rights to the data obtained. With further positive preclinical results, the Company will strengthen OsteoDex commercially in an out-licensing perspective. The value of the market for breast cancer drugs (total sales) in the US, Western Europe and Japan is estimated to be more than USD 15 billion in 2022 (Decision Resources 2013). The expanded preclinical program is part of the company's strategy to show the potential of OsteoDex in addition to the indication of castration-resistant prostate cancer.

Lung cancer

DexTech has previously announced preclinical studies on the effect of OsteoDex on the most common form of lung cancer, so-called. non-small cell lung cancer (NSCLC). Conducted in vitro experiments at Karolinska Institutet, OsteoDex shows a robust cell killing effect in non-small cell lung cancer (NSCLC). The cell killing effect was found to be fully in par with that seen in castration-resistant prostate and breast cancer.

Lung cancer is divided into two main groups; non-small cell lung cancer and small cell lung cancer.

DexTech Medical

About 80 percent of all lung cancer cases are non-small cell lung cancer (NSCLC), which in turn is divided into several subgroups. Globally, > 1.5 million people die from lung cancer annually and the vast majority of them die from the same. The lack of active and well tolerable drugs is striking.

Multiple Myeloma

DexTech has completed an extensive preclinical program regarding OsteoDex' effect on multiple myeloma. Conducted in vitro tests at Karolinska Institutet show that OsteoDex has a robust cell-killing effect on myeloma cells. The cell-killing effect has been shown to be superior in comparison with the standard preparation Melphalan.

MM is a form of blood cancer that starts in the bone marrow and causes the breakdown of the skeleton. The disease is incurable and the treatments that are currently available are used to slow the progression as much as possible. The treatments often have severe side effects.

The company sees OsteoDex as very promising for the treatment of MM and has therefore decided to conduct a phase 1 study regarding OsteoDex's effect on patients with multiple myeloma. This is based on OsteoDex's dual action mechanism, inhibition of bone-degrading cells and tumor cell toxicity, and with mild side effects, verified in clinical results.

On August 10, 2022, the Swedish Medicines Agency approved and granted permission to conduct the phase 1 study regarding OsteoDex's effect on patients with multiple myeloma. The study will include 20 patients and will be conducted at 5 hospital centers in Sweden and Norway. The study is estimated to start during quarter 1 2023 at the latest and is estimated to be completed during quarter 3 2024.

PSMA binding compound

In June 2016, DexTech filed a patent application for important innovation regarding diagnosis (so-called companion diagnostics) and target-specific treatment of prostate cancer.

It is well known that prostate cancer cells on their surface overexpress the protein PSMA (prostate-specific membrane antigen, i.e., PSMA is present in greater amount on the surface of the tumor cell). Extensive international research activity is underway to produce molecules that can bind specifically to PSMA and are thus used as carriers of cancer cell killing substances (radioactive isotopes, cytostatics etc.) for so-called target specific treatment of prostate cancer. Such molecules (including antibodies to PSMA) have been produced in several laboratories, but there are still challenges regarding production for clinical use, durability, patent protection, regulatory requirements, etc.

With the help of the company's technology platform, DexTech has now developed a new PSMA-binding association. The new substance has unique properties in that it has multiple PSMA-binding moieties and can carry a greater load of cell-killing substances than has been possible with PSMA-specific molecules produced so far. The production of the new substance can be relatively easily adapted to the company's GMP platform (i.e. manufacturing approved for clinical use). The current patent application complements and strengthens the company's other patents. DexTech intends to seek a development partner for the new drug candidate's pre-clinical / clinical development.

In June 2016, DexTech filed a patent application for an important innovation (patent family 4) regarding diagnosis (so-called companion diagnostics) and target-specific treatment of prostate cancer, PSMA.

In June 2018, this application was approved for a patent in Finland. In the fall of 2017, DexTech filed an international patent application (the so-called PCT application). Patents are now approved and granted in Europe.

Patent

DexTech's patent portfolio includes four patent families containing approved patents and patent applications that provide good protection to the Company's drug candidates and the Company's technology platform. The portfolio has a geographical spread relevant to DexTech. The Company's four patent families / patent applications are strongly related, and each patent family is therefore relevant to all the Company's drug candidates and to the platform, GuaDex. Patent applications are filed in countries where there is advanced drug research and development and in the countries that constitute larger markets for pharmaceutical products.

DexTech Medical

Patent Family 1 - filed 1999

Patent Family 1 describes how the positively charged substance, CatDex, is selectively enriched in the tumor tissue, i.e. selectively relatively normal tissue.

Patent Family 1 includes approved patents in Australia, Canada, the United States, and Europe (registered in Belgium, Switzerland, Germany, France, United Kingdom, Italy and Sweden). The patent is valid until October 12, 2019.

Patent Family 2 filed in 2008

Patent Family 2, the GuaDex patent, a further development of Patent Family 1, describes its tumor cell killing properties against a variety of tumors, tumor cell cultures.

Patent Family 2 includes approved patents in China, Finland, Israel, USA, Mexico, Canada, Japan and Europe (registered in Switzerland, Germany, France, UK, Italy and Sweden). The patent is valid until March 6, 2028.

Patent Family 3 - filed in 2008

Patent Family 3, the OsteoDex patent, is a GuaDex molecule with a further component, a bisphosphonate, which has selectivity for the skeleton, i.e. where the metastasis is.

Patent family 3 includes approved patents in China, Japan, Canada, Israel, Mexico, Brazil and Europe (registered in Switzerland, Germany, France, UK, Italy and Sweden). The patent is valid until April 7, 2028.

Patent Family 4 - filed 2016

In June 2016, DexTech filed a patent application for an important innovation (patent family 4) regarding diagnosis (so-called companion diagnostics) and target-specific treatment of prostate cancer, PSMA. In June 2018, this application was approved for a patent in Finland. In the fall of 2017, DexTech filed an international patent application (the so-called PCT application). The application is approved, and patents have been granted in Europe. Patents are now approved and granted in Europe.

Outlook

DexTech's main drug candidate OsteoDex has a unique dual mode of action, tumor-specific denaturation and inhibition of bone resorbing cells (osteoclasts). OsteoDex has been studied in a clinical phase II study with good results. There are significant similarities between bone metastases from mCRPC and Multiple Myeloma, such as growth site, bone degradation and stimulation from osteoclasts.

These similarities have motivated DexTech's studies of the effects of OsteoDex on Multiple Myeloma. The company has in extensive preclinical studies conducted at Karolinska Institutet in Stockholm shown that OsteoDex has a very significant tumor cell killing effect that has been demonstrated on various Multiple Myeloma tumor cell lines. OsteoDex shows a strong effect even at low concentrations.

The project is now being further developed into clinical research and a formal protocol is being drawn up. On August 10, 2022, the Medical Products Agency approved and granted the application for a phase 1 study regarding OsteoDex's effect on patients with multiple myeloma. The study will include 20 patients and will be conducted at 5 hospital centers in Sweden and Norway. The study is estimated to start during quarter 1 2023 at the latest and is estimated to be completed during quarter 3 2024.

The intention is that the study will provide possible "proof of concept" and thereby further verify OsteoDex's great value as a potential cancer drug. The market for the new indication is estimated to be twice as large as that for mCRPC. The rights issue 2021 finances the Multiple Myeloma study and ensures continued operation until the end of 2024.

The continued clinical development of OsteoDex will be carried out by or together with a prospective licensee.

Organisation

The Board consists of Chairman Andreas Segerros and Board members Per-Olov Asplund, Rolf Eriksson, Anders R Holmberg (CEO and founder) Sten Nilsson (founder) and Svante Wadman.

The share

The DexTech share was listed on the Spotlight Stock Market on June 19, 2014. Trading takes place under the name DEX.

The number of outstanding shares at the beginning of the interim period amounted to 14,920,478. Following the rights issue, the number of shares increased by 3,565,379 shares and the number of shares at the end of the interim period thus amounted to 18,485,857.


Completed rights issue

The Extraordinary General Meeting of DexTech resolved on November 25, 2021 to approve the Board's decision of November 8, 2021 to through a rights issue. The rights issue was subscribed for a total of approximately SEK 46.35 million, including a subscription commitment of approximately SEK 0.25 million and a capitalized guarantee commitment corresponding to approximately SEK 36 million, corresponding to a total subscription ratio of approximately 80 percent. A total of 3,565,379 new shares will be issued through the rights issue. DexTech will thus receive approximately SEK 46,349,927 before issue costs of a total of SEK 9,182,143 (incl. Guarantee compensation of approximately SEK 4,635,000). A total of 551,184 shares (corresponding to approximately SEK 7.2 million) were subscribed for with the support of subscription rights, including a subscription commitment of approximately SEK 0.25 million.

The rights issue was registered on January 21, 2022 and the number of shares in DexTech thereafter amounts to 18,485,857 and the share capital to amount to SEK 831,863,565. The quota value of the share amounts to SEK 0.045. The dilution effect for the shareholders who did not participate in the rights issue amounted to approximately 19 percent.

At the end of the financial year, the share price for DexTech Medical was SEK 4.82 and the reported equity per share was SEK 2.10. The market value was MSEK 89,1. The number of shareholders was 1,253.

Development of share price per share during the financial year 2021/2022



Related party transactions

Apart from the salary of the CEO and the fee to the CFO, there are no related party transactions to report.

Accounting principles

This report has been prepared in accordance with the Annual Accounts Act and BFNAR 2012: 1 Annual Report and Consolidated Accounts (K3). The accounting principles are unchanged compared to the latest annual report.

Financial information

| | |
|----------------------------|--------------------|
| Annual report* | September 20, 2022 |
| Q1-report 2022/2023 | October 27, 2022 |
| Annual General Meeting** | October 28, 2022 |
| Half-year report 2022/2023 | February 15, 2023 |
| Q3-report 2022/2023 | April 29, 2023 |
| Year-end report 2022/2023 | August 30, 2023 |

* The annual report will be available on the Company's website www.dextechmedical.com on September 20, 2022.

** The annual general meeting will be held in Stockholm on October 28, 2022.

Contact

Anders Holmberg, CEO, +46 73 324 27 82
Gösta Lundgren, CFO, +46 70 710 47 88

This information is such information that DexTech Medical AB is required to disclose in accordance with the EU Market Abuse Regulation. The information was submitted for publication on August 30, 2022 through the care of the above contact persons.

This report is an in-house translation of the original report in Swedish

Stockholm August 30, 2022

DexTech Medical AB

Board of Directors

This report has not been reviewed by the Company's auditor.

DexTech Medical AB
Dag Hammarskjölds Väg 34A, Uppsala
Mailing address:
Box 389, 751 06 Uppsala
www.dextechmedical.com

SUMMARY OF INCOME STATEMENTS

| KSEK | Fourth quarter | | 12 months | |
|---|--------------------------|--------------------------|--------------------------|--------------------------|
| | 2022-04-01 2022-06-30 | 2021-04-01 2021-06-30 | 2021-07-01 2022-06-30 | 2020-07-01 2021-06-30 |
| Net sales | - | - | - | - |
| Work performed by the company for its own use and capitalized | 2 887 | 164 | 3 116 | 635 |
| Operating expenses | -4 942 | -1 652 | -8 385 | -6 710 |
| Operating profit/loss | -2 055 | -1 488 | -5 269 | -6 075 |
| Profit/loss before tax | -2 055 | -1 488 | -5 269 | -6 075 |
| Tax | - | - | - | - |
| Net profit/loss | -2 055 | -1 488 | -5 269 | -6 075 |
| Earnings per share, SEK * | -0,11 | -0,10 | -0,31 | -0,41 |
| Average number of shares * | 18 485 857 | 14 920 478 | 16 790 364 | 14 920 478 |

* Before and after dilution.

SUMMARY BALANCE SHEETS

| KSEK | 2022-06-30 | 2021-06-30 |
|-------------------------------------|---------------|--------------|
| Assets | | |
| Intangible assets | 3 564 | 3 478 |
| Financial assets | 1 | 1 |
| Receivables | 551 | 298 |
| Cash and cash equivalents | 35 473 | 3 457 |
| Total assets | 39 589 | 7 234 |
| Equity and liabilities | | |
| Equity | 38 878 | 7 016 |
| Current liabilities | 711 | 218 |
| Total equity and liabilities | 39 589 | 7 234 |

SUMMARY CASH FLOW ANALYSIS

| KSEK | 2021-07-01 2022-06-30 | 2020-07-01 2021-06-30 |
|---|--------------------------|--------------------------|
| Cash flow from operating activities | -2 000 | -2 000 |
| Cash flow from investing activities | -3 115 | -634 |
| Cash flow from financing activities | 37 131 | - |
| Cash flow for the period | 32 016 | -2 634 |
| Cash and cash equivalents at the beginning of the period | 3 457 | 6 091 |
| Cash and cash equivalents at the end of the period | 35 473 | 3 457 |